Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study

https://doi.org/10.1016/0002-9343(87)90490-6Get rights and content

Abstract

A long-term retrospective case-control study was performed comparing 119 patients with rheumatoid arthritis treated with cyclophosphamide and 119 matched control patients with rheumatoid arthritis not treated with cyclophosphamide to determine the risk of subsequent malignancy. Thirty-seven malignancies were detected in 29 cyclophosphamide-treated patients, while 16 malignancies were found in 16 control patients (p <0.05) during a mean follow-up period of more than 11 years. Urinary bladder cancer (six cyclophosphamide-treated patients, no control patients) and skin cancer (eight cyclophosphamide-treated patients, no control patients) were identified as differing statistically between the groups, and hematologic malignancy (five cyclophosphamide-treated patients, one control patient) showed a similar trend. Survival analysis indicated that the rate of development of malignancy in the cyclophosphamide-treated patients was significantly greater than in the control patients at six years following drug initiation, and that this increased rate persisted even at 13 years (p <0.01). Of the many risk factors evaluated, mean total cyclophosphamide dose and duration and tobacco use were significantly increased in patients in whom cancer subsequently developed. These long-term complications must be considered seriously when cyclophosphamide or other cytotoxic drugs are initiated for the treatment of rheumatoid arthritis.

Reference (43)

  • FosdickWM et al.

    Long-term cyclophosphamide therapy in rheumatoid arthritis

    Arthritis Rheum

    (1968)
  • Cooperating Clinics Committee of the American Rheumatism Association

    Controlled trial of cyclophosphamide in rheumatoid arthritis

    N Engl J Med

    (1970)
  • LidskyMD et al.

    Double-blind study of cyclophosphamide in rheumatoid arthritis

    Arthritis Rheum

    (1972)
  • WilliamsHJ et al.

    Comparison of high- and low-dose cyclophosphamide therapy in rheumatoid arthritis

    Arthritis Rheum

    (1980)
  • IannuzziL et al.

    Does drug therapy slow radiographic deterioration in rheumatoid arthritis?

    N Engl J Med

    (1983)
  • KinlenLJ et al.

    Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

    Br Med J

    (1979)
  • PennI et al.

    Immunosuppression and cancer

    Transplant Proc

    (1973)
  • SeiberSM et al.

    Toxicity of antineoplastic agents

    Adv Cancer Res

    (1975)
  • PennI

    Second malignant neoplasms associated with immunosuppressive medication

    Cancer

    (1976)
  • PollockBH et al.

    Neoplasia and cyclophosphamide

    Arthritis Rheum

    (1973)
  • WallRL et al.

    Carcinoma of the urinary bladder in patients receiving cyclophosphamide

    N Engl J Med

    (1975)
  • Cited by (233)

    • The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study: Cancer risk in AAV three subtypes

      2021, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      In a study conducted in four institutions in 2011, 1-, 2-, and 5-year survival rates improved 88%, 85%, and 78%, respectively [7]. While CYC has greatly improved the survival rate in AAV, it can lead to adverse events including renal toxicity, bone marrow suppression, opportunistic infection, hemorrhagic cystitis, and an increased occurrence of cancer [7–10]. Several studies have reported that the incidence of cancer increases in patients with AAV [7,8,11–17].

    View all citing articles on Scopus

    This work was supported in part by the Arthritis Foundation, Western Pennsylvania Chapter.

    *

    Current address: 4944 Penn Avenue South, Minneapolis, Minnesota 55409.

    View full text